The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pacira BioSciences Inc shares valued at $146,208 were sold by RIKER LAUREN on Jun 04 ’25. At $26.21 per share, RIKER LAUREN sold 5,578 shares. The insider’s holdings dropped to 59,564 shares worth approximately $1.59 million following the completion of this transaction.
Also, WILLIAMS KRISTEN sold 14,376 shares, netting a total of over 377,226 in proceeds. Following the sale of shares at $26.24 each, the insider now holds 161,574 shares.
Before that, RIKER LAUREN had added 5,579 shares to its account. In a trade valued at $146,209, the Officer bought Pacira BioSciences Inc shares for $26.21 each.
As published in a research note from Truist on January 30, 2025, Pacira BioSciences Inc [PCRX] has been rated up from a Sell to a Hold and the price target has been revised to $25 from $8. Analysts at Truist downgraded the stock from ‘”a Buy”‘ to ‘”a Sell”‘ outlook in a report released in mid August. As of August 12, 2024, RBC Capital Mkts has decreased its “an Outperform” rating to a “Sector perform” for PCRX. Earlier on August 12, 2024, Raymond James downgraded its rating. Their new recommendation was “a Mkt perform” for PCRX stock which previously was a “an Outperform”.
Analyzing PCRX Stock Performance
During the last five days, there has been a surge of approximately 3.12%. Over the course of the year, Pacira BioSciences Inc shares have jumped approximately 41.93%. Shares of the company reached a 52-week high of $27.64 on 04/08/25 and a 52-week low of $18.17 on 01/06/25.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
According to the 24-hour chart, there is a support level at 26.27, which, if violated, would cause prices to drop to 25.80. In the upper region, resistance lies at 27.18. The next price resistance is at 27.62. RSI (Relative Strength Index) is 58.17 on the 14-day chart, showing neutral technical sentiment.
